TDF was well tolerated overall; 3 patients (1.1%) discontinued the study early for an AE (2-MRI and 1-NRF). No patients had a confirmed increase in serum creatinine of ≥0.5 mg/dL, and 1% (2-NRF) had transient PO4 <2 mg/dL. Nine MRI patients had CLCr <50 mL/min (pre-treatment range: 49–61 mL/min) that stabilized with dose adjustment. No differences were observed in % change in spine or hip BMD over 96 weeks, and no clinically relevant bone loss was noted in either group. At Week 96 there was no significant difference (missing = failure) in % with HBV DNA < 400 copies/mL, or rates of ALT normalization or HBeAg loss/seroconversion. Conclusions: The

safety, PK, and efficacy of patients with MRI receiving TDF were similar to NRF patients; in MRI patients there was no evidence of increased

risk for renal- or bone-related complications. W SIEVERT,1 S STRASSER,2 E GANE,3 J GEORGE,4 F WEILERT,5 www.selleckchem.com/products/Everolimus(RAD001).html JF FLAHERTY,6 P DINH,6 KM KITRINOS,6 JG MCHUTCHISON,6 P MARCELLIN7 1Monash University and Monash Medical Centre, Melbourne, VIC; 2Royal Prince Alfred Hospital, Pirfenidone solubility dmso Sydney, NSW; 3Auckland City Hospital, Auckland, New Zealand; 4Storr Liver Unit, University of Sydney at Westmead Hospital, Sydney, NSW; 5Waikato Hospital, Hamilton, New Zealand; 6Gilead Sciences, Foster City, CA, USA; 7Hôpital Beaujon, Clichy, France. Background: We previously reported that 5 years of tenofovir DF (TDF) therapy in mostly treatment naïve patients results in sustained virological suppression with no development

of resistance and was associated with either the halting or regression of fibrosis in 96% of patients. Here we present 6 year results from these two ongoing 8 year studies (Studies 102 and 103). Methods: After 48 weeks of double-blind comparison of TDF to adefovir dipivoxil, find more all patients undergoing liver biopsy were eligible to continue open-label TDF. Patients were assessed every 3 months for safety and efficacy with annual resistance surveillance; annual assessments of bone mineral density (BMD) of the spine and hip by DXA were added starting at year 4. Results: In a total 641 patients who were initially randomized and treated, 585 (93%) entered the TDF extension phase, and at Year 6, 466 (73%) remain on study. Efficacy results at Year 6 are shown in the table. TDF was well tolerated over the 6 year evaluation period. Less than 2% of patients discontinued TDF due to an adverse event, and ≤1.5% experienced a confirmed renal event (≥0.5 mg/dL increase in serum creatinine from baseline, phosphorus <2 mg/dL, or CrCL <50 mL/min). BMD (T scores) was stable over 2 years of evaluation. No resistance to TDF has been detected through Year 6. Conclusions: In these two trials, TDF remains safe and effective over a 6 year treatment period, with no detectable resistance to TDF; a relatively low rate of renal events and no evidence of clinically relevant bone loss were also observed.